# Global Life Science Ventures

> Global Life Science Ventures is a VC fund backing Biotechnology. See 21 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: München, Germany
- Total investments: 21
- Last investment: Jun 2012
- Lead investor: 29%
- Last updated: Aug 2026
- Website: http://www.global-life-science-ventures.com/

Global Life Science Ventures is a VC fund in München focused on Biotechnology and Health Care. Global Life Science Ventures (GLSV) was a venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance,advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

## Contacts

5 contacts available for Global Life Science Ventures. Shizune tracks 3 team members at Global Life Science Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/global-life-science-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 62% |
| Health Care | 11 | 52% |
| Medical | 8 | 38% |
| Pharmaceutical | 5 | 24% |
| Genetics | 2 | 10% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 24% |
| Series A | 4 | 19% |
| Series B | 4 | 19% |
| Series D | 3 | 14% |
| Series E | 2 | 10% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 29% |
| Germany | 3 | 14% |
| Denmark | 2 | 10% |
| France | 1 | 5% |
| Austria | 1 | 5% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hans Kupper | Partner | 3 | https://shizune.co/investors/profile/hans-kupper |
| Bert van Toor | Investment Manager | 0 | https://shizune.co/investors/profile/bert-van-toor |
| Peter Reinisch | Partner | 0 | https://shizune.co/investors/profile/peter-h-reinisch |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Santaris Pharma | Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug developmentcapabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. | $12M |  | Jun 21, 2012 |  |
| Action Pharma | Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÐMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark. | $6.3M | Series C | Jul 16, 2010 |  |
| Coapt Systems | Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilizationtrays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010. | $3.7M | Debt Financing | Dec 29, 2009 |  |
| Agendia | Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests canhelp physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. |  | Series E | Sep 23, 2009 |  |
| Santaris Pharma | Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug developmentcapabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. | $22.4M | Series C | Dec 30, 2007 |  |
| Agendia | Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests canhelp physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. |  | Series D | Aug 28, 2007 |  |
| Coapt Systems | Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilizationtrays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010. | $22.6M | Series E | Mar 29, 2007 |  |
| Pieris | Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $6.4M | Series B | Nov 01, 2006 |  |
| NeurogesX | NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's leadproduct candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic pain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California. | $20M | Series D | Dec 01, 2005 |  |
| Spinal Cord Therapeutics GmbH | Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system. | $14M | Series A | Sep 19, 2005 |  |

10 of 21 investments shown.

## Co-investors
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 5 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 5 deals together
- [Boston Millennia Partners](https://shizune.co/investors/profile/boston-millennia-partners) — VC Fund, 4 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 4 deals together
- [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 3 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany)

## FAQ

### What does Global Life Science Ventures invest in?

Global Life Science Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series A stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Global Life Science Ventures?

Public channels for Global Life Science Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Global Life Science Ventures?

The team at Global Life Science Ventures includes Hans Kupper (Partner), Bert van Toor (Investment Manager) and Peter Reinisch (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co